Highlights
-- αVβ6 Integrin (RAD301) IND approval for Phase 1 trial
-- Pivalate phase 2a data presented at 34th EORTC/AACR/NCI Symposium in Barcelona
-- HER2 nanobody (RAD201) demonstrates favourable tumour targeting in breast cancer patients
-- Agreement with NorthStar Medical Radioisotopes for the supply of non-carrier added (n.c.a.) Actinium-225
-- Agreement with ANSTO for the supply of key isotope lutetium-177
-- Nature publishes encouraging data on DUNP19 receptors role in cancer growth
-- Successful completion of institutional and retail entitlement offers
For more information, download the attached PDF.
Download this document
